Latest News & Updates of Loncom Pharma

Bestcomm won "Independent Innovation Enterprise" and "Top 50 R&D Company" at the 2025–2026 Industry Conference.

Bestcomm Pharmaceutical has been named among the 2026 Top 20 Chinese Pharmaceutical CRO Enterprises by the PDI Summit. The ranking evaluates revenue, R&D investment, headcount, brand awareness, and more. As a leading one‑stop R&D solution provider, Bestcomm is committed to accelerating innovative drug development and delivering high‑quality therapies to patients.

Loncom Pharmaceutical wrapped up its 2026 Safety Production Month with record participation, practical emergency drills, and a knowledge contest. A comprehensive hazard inspection per AQ3067-2026 was completed. The company reinforces that rigorous safety management is the bedrock of drug quality and patient trust across all operations.

Biocom made a strong appearance at CPHI China 2026, hosting over 100 clients and securing dozens of cooperation intentions during the three-day event. Leveraging its full‑industry‑chain strengths and ICH‑aligned R&D, cGMP quality systems, and ISO dual certifications, the company showcased its integrated capabilities in API and FDF development, manufacturing, and global registration, while capturing key trends such as digital pharma and low‑carbon synthesis. Looking ahead, Biocom will continue to deepen its focus on high‑end APIs, accelerate AI‑driven and green manufacturing, and join global partners in driving high‑quality, sustainable growth for the pharmaceutical industry.